Erudio Healtherudio.com
Drug
Rucaparib trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying rucaparib: MiST. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 5 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| MiST NCT03654833 · University of Leicester | relapsed malignant mesothelioma | Phase 2 | 227 | 35 | Focused | Nov 1, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| TRITON3 NCT02975934 · pharmaand GmbH DeepView → | HRD metastatic castration-resistant prostate cancer | Phase 3 | Deep | View | |||
| TRITON2 NCT02952534 · pharmaand GmbH DeepView → | metastatic castration-resistant prostate cancer with HRD | Phase 2 | Deep | View | |||
| ARIEL3 NCT01968213 · pharmaand GmbH DeepView → | platinum-sensitive recurrent high-grade serous or endometrioid ovarian cancer | Phase 3 | Deep | View | |||
| BilT-02 NCT03639935 · University of Michigan Rogel Cancer Center FocusedView → | advanced or metastatic biliary tract cancer following platinum | Phase 2 | Focused | View | |||
| BrUOG360 NCT04253262 · Brown University FocusedView → | metastatic castration-resistant prostate cancer | Phase 1/Phase 2 | Focused | View | |||